Ductal Carcinoma in Situ (DCIS): Treatment & Decisions

DCIS stands for ductal carcinoma in situ. Abnormal cells have been found inside one of the milk ducts of the breast. They have not broken through the wall of that duct into the surrounding breast tissue. That is what "in situ" means. It is why DCIS is called non-invasive, and why it is staged as stage 0, the earliest stage.

It is common. The National Cancer Institute estimates that about 20% to 25% of new breast cancer diagnoses in the United States each year are DCIS. The American Cancer Society puts it at roughly 1 in 5.

The outlook is very good. NCI reports that more than 98% of people diagnosed with DCIS are alive five years later. It also reports that DCIS is less likely to come back than invasive breast cancer. The American Cancer Society says nearly all women diagnosed at this stage can be cured.

Under a microscope, the cells look like cancer cells. That is why "carcinoma" is in the name. It is also why DCIS has a place inside breast cancer staging. The paperwork, the clinic and the insurance forms all use that word.

Trusted sources still describe DCIS in noticeably different words. NCI calls it noninvasive breast cancer, intraductal carcinoma, or stage 0 breast cancer. NCI also notes it may be called precancer. The American Cancer Society calls it non-invasive or pre-invasive breast cancer.

That mixture of language arrives at the moment you least want ambiguity. Many people hear one word, cancer. Their mind goes straight to chemotherapy, to spread, to dying. The fear is understandable. What the word alone does not tell you is how contained the situation is. That comes from your pathology report. If the naming is what frightens you, say so to your team.

Most DCIS is found on a screening mammogram, before anything can be felt. On the image it usually shows up as calcifications, tiny white specks. A biopsy confirms the diagnosis and shows whether the cells have stayed inside the duct. It also gives two things that shape every conversation afterwards. The grade, and whether the cells have hormone receptors.

Grade describes how abnormal the cells look, and how quickly they are likely to grow. It is one factor a team weighs when discussing how much treatment to consider. On its own it cannot say what will happen.

Margins matter after breast-conserving surgery. A pathologist checks the rim of normal tissue around what was removed. The American Cancer Society describes the goal as at least 2 mm of cancer-free tissue around it. That lowers the chance of the DCIS returning in that breast. If the margin is not clear, more surgery may be offered. And if clear margins cannot be reached even then, mastectomy may be recommended.

Surgery. Breast-conserving surgery, or lumpectomy, removes the DCIS with a margin of surrounding tissue. Mastectomy removes the whole breast. It is usually recommended when the DCIS is large. Or when it is present in more than one separate area of the breast. Or when clear margins cannot be achieved.

Radiation. Radiation is generally given after lumpectomy, to lower the risk of the DCIS coming back in the same breast. It may be left out for some people, such as older people or those with other serious health conditions. That applies when the DCIS is small, low grade and removed with good margins.

Endocrine (hormone) therapy. If the DCIS has hormone receptors, tamoxifen or an aromatase inhibitor may be offered. The American Cancer Society reports that five years of this treatment can lower a risk. It lowers the risk of another DCIS, or an invasive cancer, developing in either breast.

Lymph nodes. Nodes are usually not removed when DCIS is treated with lumpectomy. A sentinel lymph node biopsy is often done alongside mastectomy, though. It is also done if invasive cancer turns up in the tissue removed.

One point recurs across the sources. Studies followed for more than 20 years show that lumpectomy plus radiation gives the same survival as mastectomy. Choosing the smaller operation is not choosing a worse outcome.

Here is the honest problem at the center of DCIS. NCI states that there is currently no way to tell which lesions found on screening mammograms will become invasive. So people with DCIS face a substantial risk of overdiagnosis and overtreatment. The American Cancer Society agrees there is no good way to know for sure. Some DCIS would become invasive. Some never would. Nobody can tell you today which one yours is.

Because of that uncertainty, treatment is offered to everyone. Some of it inevitably goes to people who would never have been harmed. And treatment carries its own costs. NCI has quoted Barry Kramer, then director of its Division of Cancer Prevention, noting that DCIS treatments carry potential harms. Those include complications of mastectomy, and second cancers linked to radiation.

Researchers are testing whether some people can safely skip surgery. NCI reports on a trial reported in 2024. People with low-risk DCIS who were actively monitored were no more likely to be diagnosed with invasive breast cancer after two years than people who had surgery, with or without radiation. Longer follow-up is needed to judge the long-term safety of going without surgery. Other trials are studying active surveillance with hormone therapy. Researchers are also using artificial intelligence to try to identify which DCIS is likelier to progress. Outside a trial, monitoring instead of surgery is not standard care today.

Numbers narrow the question. They cannot close it. More than one path leads to a good outcome. So the decision turns on what you weigh most. How you feel about surgery on your breast. Weeks of daily radiation appointments. Five years of endocrine therapy and its side effects. Mammograms that make you hold your breath every year. Living alongside a known unknown.

Some people are comfortable with the smallest reasonable treatment and close follow-up. Others find lingering uncertainty hard to live with, and want the most definitive option open to them. Neither response is irrational. Neither is the right answer for everyone.

What helps is getting specific. Ask what your grade, margins and receptor status say about your situation. Ask what each option would change, and what it would not. And ask whether a trial is open to you. You are allowed to hear the answers more than once before you decide.

• National Cancer Institute — Ductal Carcinoma in Situ (DCIS)
• National Cancer Institute — Advances in Breast Cancer Research
• National Cancer Institute — Risk of Breast Cancer Death is Low After a Diagnosis of Ductal Carcinoma in Situ
• National Cancer Institute — Breast Cancer Treatment (PDQ) Patient Version
• American Cancer Society — Treatment of Ductal Carcinoma in Situ (DCIS)
• American Cancer Society — Ductal Carcinoma in Situ (DCIS)